Recursion Pharmaceuticals (RXRX)
(Delayed Data from NSDQ)
$8.84 USD
+0.05 (0.57%)
Updated May 3, 2024 04:00 PM ET
After-Market: $8.84 0.00 (0.00%) 7:02 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Recursion Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 45 | 40 | 10 | 4 | 2 |
Cost Of Goods | 43 | 48 | 0 | 0 | 0 |
Gross Profit | 2 | -8 | 10 | 4 | 2 |
Selling & Adminstrative & Depr. & Amort Expenses | 352 | 237 | 193 | 89 | 65 |
Income After Depreciation & Amortization | -350 | -246 | -183 | -85 | -62 |
Non-Operating Income | 18 | 6 | -4 | -2 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -332 | -239 | -186 | -87 | -62 |
Income Taxes | -4 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -328 | -239 | -186 | -87 | -62 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -328 | -239 | -186 | -87 | -62 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -326 | -234 | -174 | -81 | -59 |
Depreciation & Amortization (Cash Flow) | 24 | 12 | 8 | 4 | 3 |
Income After Depreciation & Amortization | -350 | -246 | -183 | -85 | -62 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 207.85 | 175.54 | 125.35 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.58 | -1.36 | -1.49 | NA | NA |
Diluted Net EPS (GAAP) | -1.58 | -1.36 | -1.49 | -3.99 | NA |
Fiscal Year end for Recursion Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 10.89 | 10.53 | 11.02 | 12.13 |
Cost Of Goods | NA | 9.88 | 10.88 | 9.38 | 12.45 |
Gross Profit | NA | 1.01 | -0.34 | 1.64 | -0.31 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 99.94 | 99.21 | 83.35 | 69.55 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -98.93 | -99.55 | -81.71 | -69.86 |
Non-Operating Income | NA | 1.87 | 6.53 | 4.99 | 4.54 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -97.06 | -93.02 | -76.73 | -65.33 |
Income Taxes | NA | -4.06 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -93.00 | -93.02 | -76.73 | -65.33 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -93.00 | -93.02 | -76.73 | -65.33 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 233.16 | 214.33 | 201.42 | 191.62 |
Diluted EPS Before Non-Recurring Items | NA | -0.40 | -0.43 | -0.38 | -0.34 |
Diluted Net EPS (GAAP) | NA | -0.43 | -0.43 | -0.38 | -0.34 |